Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Crown Bioscience to Showcase Novel “in life” Platforms for Oncology

Published: Tuesday, February 11, 2014
Last Updated: Tuesday, February 11, 2014
Bookmark and Share
Company will highlight its expertise in Oncology Drug Discovery at AACR 2014.

Crown Bioscience, Inc. will be highlighting its expertise in Oncology Drug Discovery on booth #2111 at the AACR (American Association of Cancer Research) Annual Meeting, on April 5th - 9th 2014, San Diego Convention Center, San Diego, California.

Via a series of poster presentations Crown Bioscience will demonstrate its commitment to finding new ways to improve drug discovery and development, enabling clients to significantly accelerate their research programs and make better informed decisions about which compounds to progress into clinical trials.

At AACR, Crown Bioscience will unveil its novel “in life” platforms for Oncology. Building on the success of its recent agreement with Shanghai Institute of Materia Medica to develop the world’s leading mouse clinical trial (MCT) center in China, Crown Bioscience plans to continue to develop the largest and most advanced fully annotated collections of Patient-Derived Xenograft (PDX) models. PDX models “came-of-age” in 2013 with a massive growth in their application by the oncology research community.

Crown Bioscience will also provide an insight into how a large collection of high quality, highly characterized models ready for screening, enables drug discovery companies to run Phase II-like trials using PDX as human surrogate models. Crown Bioscience’s large collection of PDX models (HuPrime©) and HuBase™ (a comprehensive database of genotypic, pharmacological and clinical data of HuPrime models) enable drug discovery organizations to identify genetic signatures of disease, discover and validate biomarkers and perform human surrogate Phase II-like trials (also known as “Avatar” trials) by selecting patient responders and non-responders and evaluating efficacy in models that come from the direct lineage of a patient’s tumor.

Jean-Pierre Wery, President of Crown Bioscience comments, “Our mission is to provide the “gold-standard” collection of well-characterized models and services for drug discovery to help our clients reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic.” He continues, “Our mission is to deliver the results our customers need. As drug discovery continues to rapidly evolve, there is a growing desire to screen candidates earlier with more patient-relevant disease models - models which more closely reflect the patient situation in the clinic and therefore help improve the selection of candidates that are taken forward.”

Crown Bioscience has a global footprint, spanning three major continents in North America, Europe and Asia Pacific. The company offers a unique collection of ready-to-run, well-validated in vitro and in vivo models, model development expertise, comprehensive drug discovery platforms and global capacity to help clients quantify the real efficacy and pharmacological profile of their candidate before they move into the clinic.

As the largest supplier of translational oncology services, Crown Bioscience is committed to providing its pharmaceutical and biopharmaceutical customers with specialized techniques and services to help the world-wide research community turn cancer from an incurable into a manageable, chronic disease and discover new targets and therapies in the treatment of metabolic diseases.

At AACR, the following posters will be presented, and reprints are available from pr@mail.crownbio.com:
Patient relevant preclinical in vivo models using image-guided small animal irradiation for drug discovery
Session ID: Tumor Biology 24
Monday April 7, 2014, 1:00pm - 5:00pm, Hall A-E, Poster Section 7
In vivo and in vitro generation and characterization of EGFR-TKI resistance in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models of NSCLC with activating EGFR mutations
Session ID: Tumor Biology 47
Wednesday April 9, 2014, 8:00am - 12:00pm, Hall A-E, Poster Section 3
Modeling anti-leukemic therapy by patient derived AML xenografts with distinct phenotypes/geneotypes
Session ID: Tumor Biology 32
Tuesday April 8, 2014, 8:00am - 12:00pm, Hall A-E, Poster Section 7
Parameters influencing the design of mouse clinical trial (HuTrial™)
Session ID: Tumor Biology 18
Monday April 7, 2014, 8:00am - 12:00pm, Hall A-E, Poster Section 9
Evaluate in vivo efficacy of anti-tumor immuno-therapeutics using Mixeno™ mouse models
Session ID: Immunology 4
Monday April 7, 2014, 1:00pm - 5:00pm, Hall A-E, Poster Section 27
Xenograft models for development of new drugs targeting fibroblast growth factor receptor (FGFR)
Session ID: Tumor Biology 32
Tuesday April 8, 2014, 8:00am - 12:00pm, Hall A-E, Poster Section 7
X-MAN™ isogenic DualXeno™ models with KRAS mutation predicts the effect of anti-EGFR agents
Session ID: Tumor Biology 32
Tuesday April 8, 2014, 8:00am - 12:00pm, Hall A-E, Poster Section 7


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crown Bioscience Acquires Molecular Response’s PDX Business
Company is acquiring all of Molecular Response’s existing PDX models.
Friday, February 13, 2015
Crown Bioscience Expands Operations and Re-Brands UK Site
Existing facility will become centre of excellence for hormonal oncology and step up European operations.
Friday, January 09, 2015
Crown Bioscience Announces U.S. Expansion
New service center will allow the expansion of new immunotherapy experimental platforms to advance translational medical research and the treatment of cancers.
Saturday, October 25, 2014
Crown Bioscience President Honored in PharmaVOICE 100
Dr Jean-Pierre Wery is recognized for pioneering work in translational medicine, improving the efficiency of drug discovery and development.
Friday, August 01, 2014
Crown Bioscience to Showcase Progression in Human Surrogate Trials
HuTrialTM demonstrates commitment to furthering preclinical understanding in order to improve personal care and increase patient recovery rates.
Wednesday, May 21, 2014
Crown Bioscience Receives $26.55M Series D Funding
Investment will fund rapid expansion in translational platform technologies for oncology and metabolic diseases.
Monday, May 12, 2014
Crown Bioscience Announces Research Collaboration with the NRCMM
New collaboration aims to develop disease-specific experimental models for translational medical research.
Saturday, May 10, 2014
Crown Bioscience Enters Strategic Partnership with SNBL
Agreement’s initial focus is for SNBL to promote Crown services to its Japanese client base.
Friday, April 25, 2014
Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery
Size of collection allows for more informed preclinical decision making on prospective drug candidates.
Wednesday, April 23, 2014
SIMM and Crown Bioscience Reach Landmark Agreement
Agreement to develop world-leading mouse clinical center and largest annotated PDX and translational oncology platform.
Friday, November 29, 2013
Crown Bioscience Enter Into a Business Collaboration with Xstrahl Ltd
Development of radiation models of cancer will enable the discovery of more effective oncology therapies.
Tuesday, October 15, 2013
Crown Bioscience Acquires PRECOS
Company strengthens oncology expertise.
Monday, August 05, 2013
CrownBio Strengthens Oncology Expertise with Acquisition of PRECOS
Company has acquired the shares of Preclinical Oncology Services Limited.
Tuesday, July 30, 2013
Crown Bioscience, Inc. and Horizon Discovery Announce Exclusive Two Year Agreement
Partnership to offer combined solutions for in vivo drug discovery model development.
Wednesday, April 03, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!